Description
Composition:
Each film -coated tablet contains:-
Dapagliflozin Propanediol Monohydrate
Eq. to Dapagliflozin 10mg
Sitagliptin Phosphate Monohydrate I.P
Eq. to Sitagliptin 100mg
Mechanism:
Inhibition of DPP-4 by sitagliptin slows DPP-4 mediated inactivation of incretins like GLP-1 and GIP. Incretins are released throughout the day and upregulated in response to meals as part of glucose homeostasisLabel. Reduced inhibition of incretins increase insulin synthesis and decrease glucagon release in a manner dependant on glucose concentrationsLabel. These effects lead to an overall increase in blood glucose control which is demonstrated by reduced glycosylated hemoglobin (HbA1c).
Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.
Its protective effects in heart failure is attributed primarily to haemodynamic effects, where SGLT2 inhibitors potently reduce intravascular volume through osmotic diuresis and natriuresis. This consequently may lead to a reduction in preload and afterload, thereby alleviating cardiac workload and improving left ventricular function.
Indication:
It is indicated in patients with type 2 diabetes mellitus inadequately controlled on Metformin monotherapy.
Dosage:
1 tablet once daily or to be taken in a dose and duration as directed by the Physician.